Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinical trial

Abstract Background Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) is a treatment for preventing febrile neutropenia (FN) in patients with early breast cancer. However, the optimal injection timing of PEG-rhG-CSF after chemotherapy is obscure. The trial was designed...

詳細記述

書誌詳細

主要な著者:	Yinggang Xu, Lifeng Huang, Jue Wang, Jinzhi He, Ye Wang, Weiwei Zhang, Rui Chen, Xiaofeng Huang, Jin Liu, Xinyu Wan, Wenjie Shi, Lu Xu, Xiaoming Zha
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2024-11-01
シリーズ:	BMC Cancer
主題:	Breast cancer PEG-rhG-CSF Chemotherapy Neutropenia
オンライン･アクセス:	https://doi.org/10.1186/s12885-024-13156-y
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!